JW Therapeutics Completes $300 Million Hong Kong IPO for CAR-T Products
publication date: Nov 3, 2020
JW Therapeutics, a Shanghai cell therapy company, raised $300 million in its Hong Kong IPO at a market capitalization of $1 billion. In 2016, JW was founded as a JV between Juno Therapeutics of Seattle and WuXi AppTec to bring Juno's CAR-T candidates to China. The company's NDA for its lead candidate, an anti-CD19 CAR-T therapy, is under review in China as a third-line treatment for B-cell lymphoma. JW priced its IPO at HK$23.80, the top of the expected range, but it slipped to HK$22 in its first trading session. More details....
Stock Symbols: (HK: 2126) (SHA: 603259; HK: 2359)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.